TLNRD1

Summary

TLNRD1 (talin rod domain containing 1, HGNC:13519) is a protein-coding gene on chromosome 15q25.1, encoding Talin rod domain-containing protein 1 (Q9H1K6). Actin-binding protein which may have an oncogenic function and regulates cell proliferation, migration and invasion in cancer cells.

This gene encodes a protein that is regulated by micro RNA MiR-574-3, and is thought to have an oncogenic function in human bladder cancer. A similar gene in mouse is located in a chromosomal region critical for differentiation of mesoderm, which affects embryo patterning and the formation of heart, muscle, blood, skeleton and the urogenital system. The mouse gene is expressed in early development, and in the adult.

Source: NCBI Gene 59274 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 64 total
• MANE Select transcript: NM_022566

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13519
Approved symbol	TLNRD1
Name	talin rod domain containing 1
Location	15q25.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC99595
Ensembl gene	ENSG00000140406
Ensembl biotype	protein_coding
OMIM	615466
Entrez	59274

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000267984

RefSeq mRNA: 1 — MANE Select: NM_022566 NM_022566

CCDS: CCDS10316

Canonical transcript exons

ENST00000267984 — 1 exons

Exon	Start	End
ENSE00000942934	81000923	81005788

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 95.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.0157 / max 133.1378, expressed in 1809 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
148053	8.4281	1760
148054	5.8000	1700
148055	3.7876	970

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	95.64	gold quality
lower lobe of lung	UBERON:0008949	93.59	gold quality
cardiac muscle of right atrium	UBERON:0003379	91.34	gold quality
left ventricle myocardium	UBERON:0006566	91.06	gold quality
pericardium	UBERON:0002407	90.88	gold quality
epithelium of mammary gland	UBERON:0003244	90.82	gold quality
mammary duct	UBERON:0001765	90.81	gold quality
pylorus	UBERON:0001166	90.68	gold quality
kidney epithelium	UBERON:0004819	90.11	gold quality
pancreatic ductal cell	CL:0002079	89.03	gold quality
cerebellar vermis	UBERON:0004720	88.89	gold quality
cauda epididymis	UBERON:0004360	88.72	gold quality
cardia of stomach	UBERON:0001162	88.68	gold quality
corpus epididymis	UBERON:0004359	88.65	gold quality
pigmented layer of retina	UBERON:0001782	88.53	gold quality
retina	UBERON:0000966	88.51	gold quality
vena cava	UBERON:0004087	88.26	gold quality
superficial temporal artery	UBERON:0001614	87.85	gold quality
decidua	UBERON:0002450	87.05	gold quality
upper arm skin	UBERON:0004263	87.05	silver quality
pharyngeal mucosa	UBERON:0000355	87.00	gold quality
parotid gland	UBERON:0001831	86.96	silver quality
synovial joint	UBERON:0002217	86.74	gold quality
cartilage tissue	UBERON:0002418	86.43	gold quality
colonic mucosa	UBERON:0000317	86.30	gold quality
myocardium	UBERON:0002349	86.26	silver quality
trachea	UBERON:0003126	86.25	gold quality
inferior vagus X ganglion	UBERON:0005363	86.25	gold quality
thymus	UBERON:0002370	86.17	gold quality
seminal vesicle	UBERON:0000998	85.91	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.79
E-CURD-10	no	117.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

102 targeting TLNRD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337

Literature-anchored findings (GeneRIF, showing 2)

• Authors demonstrate that miR-574-3p is a miRNA with tumor suppressor function and that MESDC1 (which has a potential oncogenic function in BC) may be targeted by miR-574-3p. (PMID:22179486)
• Talin rod domain-containing protein 1 (TLNRD1) is a novel actin-bundling protein which promotes filopodia formation. (PMID:34264272)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tlnrd1	ENSDARG00000079017
mus_musculus	Tlnrd1	ENSMUSG00000070462
rattus_norvegicus	Tlnrd1	ENSRNOG00000012349
drosophila_melanogaster	rhea	FBGN0260442
caenorhabditis_elegans	tln-1	WBGENE00006771

Paralogs (2): TLN1 (ENSG00000137076), TLN2 (ENSG00000171914)

Protein

Protein identifiers

Talin rod domain-containing protein 1 — Q9H1K6 (reviewed: Q9H1K6)

Alternative names: Mesoderm development candidate 1

All UniProt accessions (1): Q9H1K6

UniProt curated annotations — full annotation on UniProt →

Function. Actin-binding protein which may have an oncogenic function and regulates cell proliferation, migration and invasion in cancer cells.

Subunit / interactions. May homodimerize. Interacts with F-actin.

Induction. Down-regulated by microRNA MIR574-3p.

RefSeq proteins (1): NP_072088* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR042799	TLNRD1	Family
IPR054082	Talin_IBS2B	Domain

Pfam: PF21896

UniProt features (21 total): helix 12, strand 3, initiator methionine 1, chain 1, turn 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6XZ3	X-RAY DIFFRACTION	2.19
6XZ4	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H1K6-F1	88.40	0.79

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 150 (showing top): AREB6_03, AP4_Q6, CREBP1_Q2, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, CREB_Q4, HIF1_Q3, ATF4_Q2, GOMF_ACTIN_BINDING, LEF1_Q6, YAMAZAKI_TCEB3_TARGETS_UP, CCCNNGGGAR_OLF1_01, AP2_Q6_01, ATGTTTC_MIR494, GOCC_ACTIN_FILAMENT_BUNDLE

GO Biological Process (0):

GO Molecular Function (3): actin binding (GO:0003779), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (1): stress fiber (GO:0001725)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeletal protein binding	1
protein binding	1
binding	1
actomyosin	1
contractile actin filament bundle	1

Protein interactions and networks

STRING

484 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TLNRD1	MESD	Q14696	548
TLNRD1	VCL	P18206	413
TLNRD1	KANK1	Q14678	383
TLNRD1	ZNF736	B4DX44	370
TLNRD1	TMC3	Q7Z5M5	367
TLNRD1	ITGB8	P26012	348
TLNRD1	SCAND1	P57086	344
TLNRD1	NALCN	Q8IZF0	330
TLNRD1	UTP3	Q9NQZ2	330
TLNRD1	J3QSS9	J3QSS9	329
TLNRD1	ZNF140	P52738	323
TLNRD1	MOSMO	Q8NHV5	323
TLNRD1	COX19	Q49B96	320
TLNRD1	KANSL1L	A0AUZ9	317
TLNRD1	ILK	P57043	310

IntAct

23 interactions, top by confidence:

A	B	Type	Score
CCM2	KRIT1	psi-mi:“MI:0914”(association)	0.960
CCM2	TLNRD1	psi-mi:“MI:0915”(physical association)	0.740
MAFK	BACH1	psi-mi:“MI:0914”(association)	0.730
CDC123	EIF2S2	psi-mi:“MI:0914”(association)	0.710
SH2B2	TLNRD1	psi-mi:“MI:0915”(physical association)	0.560
TLNRD1	PICK1	psi-mi:“MI:0915”(physical association)	0.560
TLNRD1	TLNRD1	psi-mi:“MI:0915”(physical association)	0.560
TLNRD1	KRIT1	psi-mi:“MI:0914”(association)	0.530
PLA2G5	MANBA	psi-mi:“MI:0914”(association)	0.350
CCL15	MLYCD	psi-mi:“MI:0914”(association)	0.350
AVPR2	ATP9B	psi-mi:“MI:0914”(association)	0.350
CHI3L1	IGF1R	psi-mi:“MI:0914”(association)	0.350
IL12A	PTX3	psi-mi:“MI:0914”(association)	0.350
TLNRD1	STK25	psi-mi:“MI:0914”(association)	0.350
TLNRD1	SH2B2	psi-mi:“MI:0915”(physical association)	0.000
TLNRD1	CCM2	psi-mi:“MI:0915”(physical association)	0.000
TLNRD1	PICK1	psi-mi:“MI:0915”(physical association)	0.000
TLNRD1	TLNRD1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (16): MESDC1 (Affinity Capture-RNA), MESDC1 (Two-hybrid), MESDC1 (Two-hybrid), MESDC1 (Two-hybrid), SH2B2 (Two-hybrid), MESDC1 (Positive Genetic), MESDC1 (Negative Genetic), CCM2 (Affinity Capture-MS), MESDC1 (Affinity Capture-MS), ITGB1BP1 (Affinity Capture-MS), MESDC1 (Affinity Capture-MS), KRIT1 (Affinity Capture-MS), MESDC1 (Affinity Capture-RNA), MESDC1 (Cross-Linking-MS (XL-MS)), ZNF257 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A3B6UES5, A0A3G2LGI8, D3ZHV2, G8JYB2, O46037, O60437, P0CE94, P0CE95, P11533, P12003, P18206, P19826, P26039, P26231, P26234, P30427, P33338, P35220, P35221, P54939, P85972, P90947, Q02328, Q03001, Q04615, Q15149, Q17162, Q3MHM6, Q54K81, Q54MH2, Q59I72, Q64727, Q6ZWR6, Q71LX4, Q8MSU4, Q91ZU6, Q95XZ0, Q9ERE8, Q9H1K6, Q9MBF8

Diamond homologs: Q9ERE8, Q9H1K6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	59
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

75 predictions. Top by Δscore:

Variant	Effect	Δscore
15:81001081:G:GT	donor_gain	0.9900
15:81001148:G:GT	donor_gain	0.9500
15:81001007:A:T	donor_gain	0.8700
15:81001006:G:GT	donor_gain	0.8300
15:81001087:G:GT	donor_gain	0.8200
15:81001081:G:T	donor_gain	0.8000
15:81001092:T:G	donor_gain	0.7800
15:81001091:T:TG	donor_gain	0.7500
15:81001077:A:T	donor_gain	0.7400
15:81001086:G:A	donor_gain	0.7300
15:81001090:G:A	donor_gain	0.7300
15:81001238:G:GT	donor_gain	0.6900
15:81001082:A:T	donor_gain	0.6800
15:81003298:GCTT:G	donor_gain	0.6700
15:81001084:GCGG:G	donor_gain	0.6600
15:81001089:T:TA	donor_gain	0.6600
15:81001056:CCGAG:C	donor_loss	0.6500
15:81001057:CGAG:C	donor_loss	0.6500
15:81001058:GAGGT:G	donor_loss	0.6500
15:81001059:AGG:A	donor_loss	0.6500
15:81001060:GGTG:G	donor_loss	0.6500
15:81001061:GTG:G	donor_loss	0.6500
15:81001062:T:G	donor_loss	0.6500
15:81001083:AGCG:A	donor_gain	0.6300
15:81001148:G:T	donor_gain	0.6300
15:81001172:C:T	donor_gain	0.6300
15:81001063:G:GT	donor_gain	0.5900
15:81001055:TCCGA:T	donor_loss	0.5800
15:81001323:G:T	donor_gain	0.5800
15:81001063:GAA:G	donor_loss	0.5700

AlphaMissense

2305 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:81002532:G:C	K87N	1.000
15:81002532:G:T	K87N	1.000
15:81002543:T:C	I91T	1.000
15:81003143:G:A	G291D	1.000
15:81002414:C:A	A48D	0.999
15:81002537:T:A	L89H	0.999
15:81002537:T:C	L89P	0.999
15:81002543:T:A	I91N	0.999
15:81002543:T:G	I91S	0.999
15:81002636:T:C	L122P	0.999
15:81002656:G:C	A129P	0.999
15:81002660:C:A	A130D	0.999
15:81002662:T:G	Y131D	0.999
15:81002912:T:C	F214S	0.999
15:81003065:C:A	A265D	0.999
15:81003139:G:C	G290R	0.999
15:81003140:G:A	G290D	0.999
15:81003149:T:C	M293T	0.999
15:81003150:G:A	M293I	0.999
15:81003150:G:C	M293I	0.999
15:81003150:G:T	M293I	0.999
15:81003151:A:C	S294R	0.999
15:81003153:C:A	S294R	0.999
15:81003153:C:G	S294R	0.999
15:81003164:C:A	A298D	0.999
15:81003166:T:C	C299R	0.999
15:81003176:T:C	L302P	0.999
15:81003277:G:C	G336R	0.999
15:81003278:G:A	G336D	0.999
15:81003290:T:C	L340P	0.999

dbSNP variants (sampled 300 via entrez): RS1001066427 (15:81003631 C>T), RS1001604444 (15:81005747 A>G,T), RS1002230626 (15:81003992 T>A), RS1002361611 (15:80999372 G>A,C), RS1002412511 (15:80999137 T>C,G), RS1002456163 (15:81006050 T>C), RS1002817227 (15:81003063 C>A,T), RS1002881777 (15:81004243 T>G), RS1003557142 (15:81002201 C>A,T), RS1003938731 (15:81006044 A>C,G), RS1004325045 (15:81000628 G>C,T), RS1005037685 (15:81005663 A>C), RS1005588418 (15:81001541 G>C), RS1005817894 (15:80999783 G>A,C,T), RS1005849846 (15:81002756 A>G,T)

Disease associations

OMIM: gene MIM:615466 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): long QT syndrome (MONDO:0002442)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005951_10	Body mass index	2.000000e-08
GCST010866_63	Coronary artery disease	4.000000e-10
GCST011365_109	Myocardial infarction	7.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	4
Benzo(a)pyrene	increases expression	2
Nickel	increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects expression, increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
bisphenol A	increases expression	1
lead acetate	increases expression	1
methylparaben	increases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
ferrous chloride	decreases expression	1
cupric chloride	increases expression	1
cupric oxide	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
ICG 001	decreases expression	1
eprenetapopt	affects expression, affects reaction	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Vorinostat	decreases expression	1
Acetaminophen	increases expression	1
Coumestrol	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Melphalan	increases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea